These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 12668652)

  • 1. Practical management of patients with chronic myeloid leukemia receiving imatinib.
    Deininger MW; O'Brien SG; Ford JM; Druker BJ
    J Clin Oncol; 2003 Apr; 21(8):1637-47. PubMed ID: 12668652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
    Usui N
    Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal transduction inhibitors (STI571): molecularly targeted therapy.
    Corujo Y; Cáceres W
    P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
    Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
    Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
    Cashen A; DiPersio JF; Khoury H
    J Clin Oncol; 2003 Nov; 21(22):4255-6. PubMed ID: 14615462
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 9. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific targeted therapy of chronic myelogenous leukemia with imatinib.
    Deininger MW; Druker BJ
    Pharmacol Rev; 2003 Sep; 55(3):401-23. PubMed ID: 12869662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
    Yamaguchi M; Konishi I
    Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
    Hasselbalch HC
    Ugeskr Laeger; 2002 May; 164(22):2914-7. PubMed ID: 12082821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
    White D; Saunders V; Grigg A; Arthur C; Filshie R; Leahy MF; Lynch K; To LB; Hughes T
    J Clin Oncol; 2007 Oct; 25(28):4445-51. PubMed ID: 17906206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib as a paradigm of targeted therapies.
    Druker BJ
    Adv Cancer Res; 2004; 91():1-30. PubMed ID: 15327887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
    Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
    Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
    Breccia M; Carmosino I; Russo E; Morano SG; Latagliata R; Alimena G
    Eur J Haematol; 2005 Feb; 74(2):121-3. PubMed ID: 15654902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.